Programmed Cell Death (PCD): Apoptosis, Autophagic PCD, or Others?

Abstract

The occurrence of cell death as a physiological event in multicellular organisms has been known for more than 150 years; in 1972 the term apoptosis was introduced on morphological grounds. However, accumulating evidence suggests that programmed cell death (PCD) is not confined to apoptosis, but that cells use different pathways for active self‐destruction as reflected by different morphology: condensation prominent, type I or apoptosis; autophagy prominent, type II; etc. Autophagic PCD appears to be a phylogenetically old phenomenon; it may occur in physiological and disease states. We have studied the relation between morphological and biochemical events during autophagic and apoptotic PCD in human mammary, lymphoblast, and colon cancer cells using electron microscopy and proteom analysis. We find that autophagic cell death (type II) PCD includes degradation of Golgi apparatus, polyribosomes, and endoplasmic reticulum, which precedes nuclear destruction. Intermediate and microfilaments are largely preserved; presumably the cytoskeleton is required for autophagocytosis. Apoptosis (type I) PCD is characterized by condensation of cytoplasm and preservation of organelles; cytoskeletal elements disintegrate in early stages. Either type of PCD involves synthesis of distinct proteins. Finally, both types of PCD share features some of a cell's stress response (e.g., translocation of hsp90). In conclusion our findings support the concept that autophagic cell death is a separate pathway of PCD distinctly different from “classical” apoptosis. However, autophagic and apoptotic PCD should not be considered as mutually exclusive phenomena. Rather, they appear to reflect a high degree of flexibility in a cell's response to changes of environmental conditions, both physiological or pathological.

Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells

“…However, there are also reports showing that inhibition of autophagy suppresses cancer cell death by anticancer reagents, indicating that autophagy can be a potential contributor to cell death. 43,47 Thus, the involvement of autophagy in cancer cell death is still controversial, probably because the molecules which execute cell death in autophagy have not been thoroughly identified.…”

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

“…However, excess autophagy can induce type II programmed cell death (autophagic cell death). 34 To study the role of autophagy in HDAC inhibitor-induced cytotoxicity, cells were pretreated with 3-MA stress: ER transmembrane eIF2α protein kinase (PERK), serine/threonine kinases inositol-requiring enzyme-1 (IRE1) and transcription factor 6 (ATF6). 47 An immediate response to protein overload in ER is the activation of PERK to phosphorylate eukaryotic translation initiation factor alpha (eIF2α) which then induces expression of a transcription factor CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP/ GADD153).…”

Impairing the bioenergetic status and the biogenesis of mitochondria triggers mitophagy in yeast

“…However, the completion of this 'self-eating process' will ultimately lead to cell death and hence, autophagy is also envisaged in higher eukaryotes as a programmed cell death (PCD). 3 Central to this programme that controls the balance between biosynthesis and degradation is Target Of Rapamycin (TOR), a phosphatidylinositol kinase-related protein kinase that is conserved from yeast to mammals. In response to nutrients, TOR controls cell growth through the regulation of translation, ribosome biosynthesis, and transcription of a subset of mRNAs.…”